Save up -80% on Ecallantide
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Kalbitor
|$29,016.38||2 cartons (3 vials)/10 mg/ml|
|Price with discount in nearest pharmacy. Price may vary.|
We offer free Ecallantide coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Ecallantide every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Ecallantide volume of distribution
The volume of distribution was 26.4 ± 7.8 L in healthy individuals. Intravenous and subcutaneous administration of ecallantide in patients and in healthy subjects resulted in rapid distribution in the vascular compartment.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Ecallantide
Ecallantide, a novel Kunitz domain produced by phage display (a powerful method of generating novel binders to potentially therapeutic targets), is a potent and selective inhibitor of plasma kallikrein which demonstrates a useful efficacy/safety ratio in the treatment of acute attacks of HAE (Hereditary Angioedema). On November 27, 2009, ecallantide was approved by the FDA for the treatment of acute attacks of hereditary angioedema for persons over 16 years of age.
Ecallantide mechanism of action
HAE is caused by a mutation of the C1-inhibitor gene. Defective or missing C1-inhibitor permits activation of kallikrein, a protease that is responsible for liberating bradykinin from its precursor kininogen. An excess of bradykinin leads to fluid leakage from blood vessels, causing swelling of tissues typical of HAE. Ecallantide suppresses this pathogenetic mechanism by selectively and reversibly inhibiting the activity of plasma kallikrein.
Dosage forms of Ecallantide
|Injection, solution||subcutaneous||10 mg/mL|
Humans and other mammals
Indication of Ecallantide
Indicated for the symptomatic treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older
Toxicity of Ecallantide
While there have been no reports of overdose with ecallantide, patients with hereditary angioedema have received single doses up to 90 mg intravenously without evidence of dose-related toxicity. There are no animal or human studies to assess the carcinogenic or mutagenic potential of ecallantide. In rats receiving subcutaneous doses up to 25 mg/kg/day, there were no observable effects on fertility reproductive performance. An approximate lethal dose was identified as 25 mg/kg intravenously in rats and 5 mg/kg intravenously in rabbits.
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Ecallantide on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.